share_log

John Wiley & Sons Sees FY25 Adj. EPS $3.25-$3.60; Revenue $1.65B-$1.69B Vs $1.67B Est.

John Wiley & Sons Sees FY25 Adj. EPS $3.25-$3.60; Revenue $1.65B-$1.69B Vs $1.67B Est.

約翰·威立與兒子預計FY25調整後每股收益爲$3.25-$3.60;營業收入爲$16.5億。$16.9億對比$16.7億的預估。
Benzinga ·  12/05 21:32

FISCAL YEAR 2025 GROWTH OUTLOOK

2025財年增長展望

Wiley is reaffirming its Fiscal 2025 growth outlook based on first half results and second half indicators. Wiley's revenue outlook is driven by favorable demand trends and performance indicators. Wiley's earnings outlook is driven by expected revenue growth and cost savings, while reflecting reinvestments to scale and optimize Research, modernize infrastructure and expand GenAI content licensing and capabilities. Wiley's cash flow outlook is driven by lower restructuring payments and favorable working capital partially offset by a year-over-year swing in incentive compensation payments.

Wiley根據上半年的業績和下半年的因子重申其2025財年的增長展望。Wiley的營業收入展望受到有利的需求趨勢和業績因子的驅動。Wiley的盈利展望受到預期的營業收入增長和節約成本的驅動,同時反映出在擴大和優化研究、現代化製造行業以及擴展GenAI內容許可和能力方面的再投資。Wiley的現金流展望受到較低的重組支付和有利的營運資金的驅動,部分被年度激勵補償支付的轉變所抵消。

Quarterly phasing in the second half of the year: The Company's projected growth in the second half of its fiscal year is expected to occur in Q4 due to strong momentum and favorable comparisons in Research.

下半年的季度安排:公司預計在財年下半年的增長將發生在第四季度,因研究領域的強勁勢頭和有利對比。

Metric
($millions, except EPS)
Fiscal 2024 Results
Ex-Divestitures
Fiscal 2025 Outlook
Ex-Divestitures
Adj. Revenue* $1,617 $1,650 to $1,690
Research $1,043 Low to mid-single digit growth
Learning $574 Low-single digit growth
Adj. EBITDA* $369 $385 to $410
Adj. EPS* $2.78 $3.25 to $3.60
Free Cash Flow $114 Approx. $125
*Excludes held for sale or sold businesses
Metric
(百萬美元,除每股收益外)
2024財政年度成果
除出售資產外
2025財年展望
除出售資產外
調整後的營業收入* $1,617 $1,650到$1,690
研究 $1,043 低到中個位數的增長
學習 $574 低個位數增長
調整後EBITDA* $369 $385到$410
調整後每股收益* $2.78 $3.25到$3.60
自由現金流 $114 約125美元
*不包括待售或已售業務

The Company remains on track with its Fiscal 2026 targets.

公司仍按計劃推進2026財年的目標。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論